EUVIMEDEUVIMED entdecken
Crossref

Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk

Steven J Yakubov, Nicolas M Van Mieghem, Jae K Oh, Saki Ito, Kendra J Grubb, Daniel O'Hair, John K Forrest, Hemal Gada, Mubashir Mumtaz, G Michael Deeb, Gilbert H L Tang, Joshua D Rovin und 9 weitere

Journal of the American College of Cardiology · 2025-04 · 85 (13) · 1419-1430

DOI: 10.1016/j.jacc.2025.02.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American College of Cardiology, 2025-04. Verfasst von Steven J Yakubov und 20 weiteren Autor:innen. Beteiligte Einrichtung: Riverside Methodist, Ohio Health, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Bioprosthesis, Heart Valve Prosthesis, Postoperative Complications. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The incidence and clinical importance of bioprosthetic valve dysfunction (BVD) in patients undergoing supra-annular, self-expanding transcatheter aortic valve replacement (TAVR) or surgery is not well understood. OBJECTIVES: The purpose of this study was to evaluate the 5-year incidence and clinical outcomes of BVD in patients undergoing CoreValve/Evolut TAVR or surgery. METHODS: This post hoc analysis pooled data from the U.S. High Risk Pivotal (n = 726) and SURTAVI (n = 1,618) randomized controlled trials (RCTs), the Extreme Risk Pivotal trial (n = 608), and CoreValve Continued Access Study (n = 2,654). The primary endpoint was the incidence of BVD through 5 years from the RCTs. The association of BVD with 5-year clinical outcomes was evaluated in the pooled RCT and non-RCT populations. RESULTS: Of 5,606 patients evaluated, 3,070 (54.8%) were men, and the mean age was 82.2 ± 7.4 years. A total of 2,344 RCT patients, including 1,227 who received TAVR and 1,117 who received surgery, and 3,262 non-RCT TAVR patients were included. The rate of BVD was lower in RCT patients undergoing CoreValve/Evolut TAVR compared with surgery (9.7% vs 15.3%; subdistribution HR: 0.57; 95% CI: 0.45-0.73; P < 0.001). In the pooled RCT and non-RCT cohort, BVD was associated with increased 5-year all-cause mortality (HR: 1.49; 95% CI: 1.32-1.68; P < 0.001), cardiovascular mortality (HR: 1.76; 95% CI: 1.52-2.03; P < 0.001), and hospitalization for valve disease or worsening heart failure (HR: 1.48; 95% CI: 1.23-1.78; P < 0.001). CONCLUSIONS: Five-year valve performance was significantly better after CoreValve/Evolut TAVR compared with surgery. Development of BVD in TAVR and surgery patients was associated with worsened 5-year clinical outcomes. (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement, NCT01240902; Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement [SURTAVI], NCT01586910; Safety and Efficacy Continued Access Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement, NCT01531374).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisBioprosthesisHeart Valve ProsthesisPostoperative ComplicationsProsthesis FailureTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleHumansMaleAortic ValveFollow-Up StudiesIncidenceRisk FactorsTreatment OutcomeRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

TAVRbioprosthetic valve dysfunctiondeteriorationdurabilityfailurehemodynamics

Autor:innen und Institutionen

  • Riverside Methodist, Ohio Health, Columbus, Ohio, USA.
  • Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • Emory University School of Medicine, Atlanta, Georgia, USA.
  • Boulder Community Health, Boulder, Colorado, USA.
  • Yale University School of Medicine, New Haven, Connecticut, USA.

Zitieren

APA

Yakubov, S. J., Van Mieghem, N. M., Oh, J. K., Ito, S., Grubb, K. J., O'Hair, D., Forrest, J. K., Gada, H., Mumtaz, M., Deeb, G. M., Tang, G. H. L., Rovin, J. D., Jain, R., Windecker, S., Skelding, K. A., Kleiman, N. S., Chetcuti, S. J., Dedrick, A., Boatman, S. V., …, & Reardon, M. J. (2025). Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk. Journal of the American College of Cardiology, 85(13), 1419-1430. https://doi.org/10.1016/j.jacc.2025.02.009

Vancouver

Yakubov SJ, Van Mieghem NM, Oh JK, Ito S, Grubb KJ, O'Hair D, et al. Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk. Journal of the American College of Cardiology. 2025;85(13):1419-1430. doi:10.1016/j.jacc.2025.02.009

BibTeX
@article{Yakubov2025,
  author = {Yakubov, Steven J and Van Mieghem, Nicolas M and Oh, Jae K and Ito, Saki and Grubb, Kendra J and O'Hair, Daniel and Forrest, John K and Gada, Hemal and Mumtaz, Mubashir and Deeb, G Michael and Tang, Gilbert H L and Rovin, Joshua D and Jain, Renuka and Windecker, Stephan and Skelding, Kimberly A and Kleiman, Neal S and Chetcuti, Stanley J and Dedrick, Alexandra and Boatman, Sarah Verdoliva and Popma, Jeffrey J and Reardon, Michael J},
  title = {Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk},
  journal = {Journal of the American College of Cardiology},
  year = {2025},
  volume = {85},
  number = {13},
  pages = {1419--1430},
  doi = {10.1016/j.jacc.2025.02.009}
}
Kostenlos starten →